Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Naim Alkhouri, M.D., currently serves as a Staff Physician with Digestive Disease Institute and Cleveland Clinic’s Children’s Hospital.
Dr. Alkhouri is board certified in internal medicine and pediatrics. He completed his medical degree at the University of Damascus, Damascus, Syria. His post-graduate training includes a one-year internal medicine and pediatric internship followed by a three-year internal medicine and pediatric residency at Albert Einstein Medical Center in Philadelphia; a three-year pediatric gastroenterology, hepatology and nutrition fellowship at Cleveland Clinic; and finally, an Adult Transplant Hepatology fellowship at the Digestive Disease Institute, Cleveland Clinic.
Dr. Alkhouri is a member of several professional organizations, including the American Association for the Study of Liver Disease; American Gastroenterology Association; American College of Gastroenterology; and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.
Among many research awards over the years, Dr. Alkhouri recently received the American College of Gastroenterology Junior Faculty Development Award to investigate volatile organic compounds in the breath of patients with liver disease. He also received the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Fellow Research Award for his prospective evaluation of the pediatric NAFLD fibrosis index and ELF markers in children with fatty liver disease.
Dr. Alkhouri is an established clinical and basic researcher and has published multiple research articles in peer-reviewed journals, textbook chapters, as well as having contributed abstracts and presentations at a number of professional association meetings.
Dr. Alkhouri’s specialty interests include nonalcoholic fatty liver disease, viral hepatitis, autoimmune liver disease, metabolic liver disease, end stage liver disease, liver transplantation, and alpha-1 antitrypsin deficiency.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Alkhouri's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.